Unbiased Analysis of Today's Healthcare Issues
That is the title of my commentary with co-authors Kathy Lang and Ross Maclean in the Journal of Clinical Pathways. The abstract is below. What is the right price for a new treatment for COVID-19? One common approach—which is frequently used worldwide and in the United States by the Institute of Clinical and Economic Review—measures…
Tomorrow, Monday, May 18, I will be moderating a panel with Dr. Bapu Jena of Harvard University, Elizabeth Oyekan of PRECISIONvalue and Michael Barr of National Committee for Quality Assurance (NCQA). The topic is: WILL ALTERNATIVE PAYMENT MODELS INCENTIVIZE HEALTH SYSTEMS TO PRESCRIBE HIGH VALUE MEDICATIONS AND SUPPORT BETTER CLINICAL OUTCOMES? ISSUE:Recent decades have seen…
The 2019 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting has kicked off in New Orleans. One interesting Panel that I am moderating is titled “How much should we – and can we- pay for gene therapies?” I am serving as the moderator and the panelists on this issue panel include: Anupam B.…
For those who are attending the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) conference this next week in Baltimore, please check out my poster titled: THE EFFECT OF MEDICATION CHOICE AFTER TUMOR NECROSIS FACTOR INHIBITOR (TNFI) USE ON THE HEALTHCARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN INSTRUMENTAL VARIABLES APPROACH My co-authors are Ahva…
Over the past few days, I have been attending the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Annual Conference in Boston. The session had a number of interesting presentations. While I was not able to catch them all, below are links to a few highlights. Darius Lakdawalla, Defining and Measuring Value in Healthcare…
The International Society For Pharmacoeconomics and Outcomes Research (ISPOR) has put together a database of databases from around the world. The ISPOR International Digest of Databases has goal is to organize global health care databases into searchable models. Their working group on this topic is chaired by Carl Asche and Elisabeth Oehrlein. If you have…
Cost effectiveness analysis (CEA) aims to examine whether the benefits of a treatment outweigh the costs. However, whenever one is conducting a CEA a key question is benefits to whom and costs to whom. For instance, a modestly efficacious drug may be cost effective from the patient’s perspective if all or most costs are covered by insurance.…